Transforming How Lower-Middle Market Healthcare Firms are Represented

 

On this episode of I Don’t Care, Host Kevin Stevenson talked with Mike Moran, Mark Thomas, and Andre Ulloa, Co-Founders, and Partners, M&A Healthcare Advisors, a boutique advisory firm whose focus is on the healthcare industry. They offer consulting and valuation services for those in the lower-middle markets looking to merge or sell their healthcare business.

M&A recently launched their advisory firm to represent small to midsize healthcare firms. There has been a recent boom of healthcare mergers and acquisitions as the economy recovers from the 2020 windfall. MAHA focuses on the under-represented, smaller-to-mid-sized healthcare firms that are considering the M&A process to sell their business.

The country continues to reopen, which is leading to healthcare providers pursuing M&A opportunities in hopes of increasing their market share and diversify their offerings. Smaller providers might face a choice to sell their companies or find a partner to help them gain access to strategic, clinical, and financial resources. MAHA plans to focus on these smaller and mid-sized businesses with larger institutional transactional support that is typically seen at larger firms.

“We’re trying to create a platform where we’re more than someone that’s just listing a business on the market,” Ulloa said. “We want to work with our clients much like an investment banker would to give them information about the market trends, let them understand what’s happening within their business that could help them improve their value in the market.”

Ultimately, they want to help these businesses achieve a successful outcome. MAHA’s strategy focuses on high-touch and high engagement with the client while also knowing the buyer community.

Follow us on social media for the latest updates in B2B!

Image

Latest

cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More
organoids
Growing the Future of Cancer Research: Inside the Promise of Organoids
April 19, 2025

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…

Read More